Literature DB >> 27630139

BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.

Mohammad Althubiti1, Miran Rada2, Jesvin Samuel3, Josep M Escorsa3, Hishyar Najeeb4, Koon-Guan Lee5, Kong-Peng Lam5, George D D Jones4, Nickolai A Barlev6, Salvador Macip7.   

Abstract

p53 is a tumor suppressor that prevents the emergence of transformed cells by inducing apoptosis or senescence, among other responses. Its functions are regulated tightly by posttranslational modifications. Here we show that Bruton's tyrosine kinase (BTK) is a novel modulator of p53. We found that BTK is induced in response to DNA damage and p53 activation. BTK induction leads to p53 phosphorylation, which constitutes a positive feedback loop that increases p53 protein levels and enhances the transactivation of its target genes in response to stress. Inhibiting BTK reduced both p53-dependent senescence and apoptosis. Further, BTK expression also upregulated DNA damage signals and apoptosis. We conclude that despite being involved in oncogenic signals in blood malignancies, BTK has antineoplastic properties in other contexts, such as the enhancement of p53's tumor suppressor responses. Along with evidence that BTK expression correlates with good prognosis in some epithelial tumors, our findings may encourage a reevaluation of the clinical uses of BTK inhibitors in cancer therapy. Cancer Res; 76(18); 5405-14. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27630139     DOI: 10.1158/0008-5472.CAN-16-0690

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Kinomics platform using GBM tissue identifies BTK as being associated with higher patient survival.

Authors:  Sofian Al Shboul; Olimpia E Curran; Javier A Alfaro; Fiona Lickiss; Erisa Nita; Jacek Kowalski; Faris Naji; Rudolf Nenutil; Kathryn L Ball; Radovan Krejcir; Borivoj Vojtesek; Ted R Hupp; Paul M Brennan
Journal:  Life Sci Alliance       Date:  2021-10-13

2.  Knockout of Bruton's tyrosine kinase in macrophages attenuates diabetic nephropathy in streptozotocin-induced mice.

Authors:  Zhe Fan; Yuanyuan Li; Lingling Xia; Yonggui Wu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

3.  BTK blocks the inhibitory effects of MDM2 on p53 activity.

Authors:  Miran Rada; Mohammad Althubiti; Akang E Ekpenyong-Akiba; Koon-Guan Lee; Kong Peng Lam; Olga Fedorova; Nickolai A Barlev; Salvador Macip
Journal:  Oncotarget       Date:  2017-11-20

4.  Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers.

Authors:  Akram I Alwithenani; Mohammad A Althubiti
Journal:  Saudi J Med Med Sci       Date:  2020-04-17

5.  CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia.

Authors:  Anthony Quagliano; Anilkumar Gopalakrishnapillai; E Anders Kolb; Sonali P Barwe
Journal:  Blood Adv       Date:  2020-09-22

6.  Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors.

Authors:  Erika Rimondi; Elisabetta Melloni; Arianna Romani; Veronica Tisato; Fabio Casciano; Gian Matteo Rigolin; Daniela Milani; Claudio Celeghini; Giorgio Zauli; Paola Secchiero; Rebecca Voltan
Journal:  Curr Oncol       Date:  2021-07-01       Impact factor: 3.677

7.  Spleen Tyrosine Kinase Inhibition Modulates p53 Activity.

Authors:  Mohammad Althubiti
Journal:  J Cell Death       Date:  2017-09-20

8.  Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer.

Authors:  Anna Tankiewicz-Kwedlo; Justyna Magdalena Hermanowicz; Krystyna Pawlak; Robert Czarnomysy; Krzysztof Bielawski; Izabela Prokop; Dariusz Pawlak
Journal:  Int J Mol Sci       Date:  2018-04-23       Impact factor: 5.923

9.  BTK: a two-faced effector in cancer and tumour suppression.

Authors:  Miran Rada; Nickolai Barlev; Salvador Macip
Journal:  Cell Death Dis       Date:  2018-10-18       Impact factor: 8.469

10.  Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival.

Authors:  Ti'ara L Griffen; Eric B Dammer; Courtney D Dill; Kaylin M Carey; Corey D Young; Sha'Kayla K Nunez; Adaugo Q Ohandjo; Steven M Kornblau; James W Lillard
Journal:  BMC Med Genomics       Date:  2021-06-29       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.